CSL N logo

CSL BMV:CSL N Stock Report

Last Price

Mex$3.64k

Market Cap

Mex$1.7t

7D

0%

1Y

n/a

Updated

28 Apr, 2023

Data

Company Financials +

CSL N Stock Overview

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.

CSL N fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance2/6
Financial Health4/6
Dividends0/6

CSL Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share PriceAU$3,635.42
52 Week HighAU$3,635.42
52 Week LowAU$3,635.42
Beta0.20
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-15.46%
5 Year Changen/a
Change since IPO27.33%

Recent News & Updates

Recent updates

Shareholder Returns

CSL NMX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how CSL N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how CSL N performed against the MX Market.

Price Volatility

Is CSL N's price volatile compared to industry and market?
CSL N volatility
CSL N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: CSL N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CSL N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
191630,000Paul McKenziewww.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSL N fundamental statistics
Market capMex$1.73t
Earnings (TTM)Mex$38.12b
Revenue (TTM)Mex$210.68b

45.3x

P/E Ratio

8.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSL N income statement (TTM)
RevenueUS$11.70b
Cost of RevenueUS$5.56b
Gross ProfitUS$6.15b
Other ExpensesUS$4.03b
EarningsUS$2.12b

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.39
Gross Margin52.52%
Net Profit Margin18.09%
Debt/Equity Ratio59.7%

How did CSL N perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

51%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.